Skip to main content

David Charles Montefiori

Professor in Surgery
Surgery, Surgical Sciences
Box 2926 Med Ctr, Durham, NC
Surgical Oncology Res Fac, Durham, NC 27710

Selected Grants


CAVIMC 2022-2026 Grant Renewal

ResearchPrincipal Investigator · Awarded by Bill and Melinda Gates Foundation · 2016 - 2026

CISA 2023-03 Task 4 Lead - COVID immunogenicity

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2026

Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study

ResearchCo Investigator · Awarded by Uvax Bio, LLC · 2024 - 2026

Interdisciplinary Research Training Program in AIDS

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025

CIVICS A - Option 21A Equitable Adjustment

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

CAVIMC 2022-2026 Grant Renewal

ResearchPrincipal Investigator · Awarded by Bill and Melinda Gates Foundation · 2016 - 2026

CISA 2023-03 Task 4 Lead - COVID immunogenicity

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2026

Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study

ResearchCo Investigator · Awarded by Uvax Bio, LLC · 2024 - 2026

Interdisciplinary Research Training Program in AIDS

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025

CIVICS A - Option 21A Equitable Adjustment

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

CIVICS A - Option 21A

ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2025

Neutralizing Antibody Assessment for SARS-CoV-2 Vaccine Trials

ResearchPrincipal Investigator · Awarded by Vaccine Company, Inc. · 2023 - 2025

Nonhuman Primate Option 6

ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2025

Moderma COVID/Flu 1083-P301

ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2024 - 2025

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 5

ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2024

HVTN Laboratory Center: Phase 1 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024

HIV Vaccine Trials Network Laboratory Center

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024

CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024

CISA Maternal COVID Immunogenicity

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

CISA COVID Peds Immunogenicity

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

EQAPOL SARS CoV-2 Option 46

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2022 - 2024

CISA COVID Flu Immunogenicity

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment

ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

Duke CTSA (TL1) Year 5

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

HVTN Supplement 2022

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023

CIVICs A - Option 18C

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2023

Moderna mRNA-1273 P201 (Part B) Trial Neutralizing Antibody Assessment

ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

CIVICs A - Option 18B SAVE Aim 3

ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2023

EQAPOL SARS CoV-2 Option 44

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2021 - 2022

Neutralizing antibody assessment for EID 030 SARS-CoV-2 Vaccine Phase I trial

ResearchPrincipal Investigator · Awarded by Henry M. Jackson Foundation · 2021 - 2022

CIVICs A - Option 18A SAVE Aims 1, 2

ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2022

HVTN Laboratory Center: Phase 1 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

CoVPN 5001 A prospective study of acute immune responses to SARS-CoV2 infection - LAB

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

EQAPOL SARS CoV-2 EQA Option 43

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2021 - 2021

EQAPOL SARS CoV-2 EQA Option 42

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2020 - 2021

Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT

ResearchCollaborator · Awarded by National Institutes of Health · 2016 - 2021

Primate Contract Expansion for Covid-19

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2021

Protocol Development Assays

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2019 - 2020

HVTN Laboratory Center: HVTN 704

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2020

HVTN Laboratory Center: HVTN Phase 1

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2020

HVTN Laboratory Center: HVTN 117

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018

HVTN Laboratory Center: HVTN 118

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018

RAMP Scholar Award Shay Behrens

ResearchPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2016 - 2018

HIV Vaccine Trials Network: LC P5 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018

Nonhuman Primate Core-Option 6

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2018

Option 13 Non Human Primate Core

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2018

Option 19 Non Human Primate Core

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2017

LC: HIV Vaccine Trials Network: Phase 1 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

HIV Vaccine Trials Network: LC P5 PF

ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015

HIV Envelope-specific functional antibody responses in HIV-exposed, HIV-vaccinated infants

ResearchCollaborator · Awarded by National Institutes of Health · 2012 - 2015

Methods to Determine HIV Transport and Inactivation by Microbicide Coating Layers

ResearchSignificant Contributor · Awarded by National Institutes of Health · 2009 - 2012

Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2012

Central Laboratory for the HIV Vaccines Trial Network

ResearchCo Investigator · Awarded by National Institutes of Health · 2000 - 2006

A Universal Env Immunogen for all HIV-1 Subtypes

ResearchConsultant · Awarded by National Institutes of Health · 2003 - 2006

Same

ResearchAdministrative Assistant · Awarded by National Institutes of Health · 1997 - 2002

Host Virus Interactions During Acute Infection

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1996 - 1999

Perform Neutralizing Assays On Hiv,Siv,And Shiv, And Adopt

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1998

External Relationships


  • Moderna

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.